Top

International Journal of Clinical Oncology

Published in:

01-05-2020 | Original Article

Outcome of patients with primary retroperitoneal solitary fibrous sarcoma

Authors: Peng Luo, Zhiqiang Wu, Shiqi Chen, Lingge Yang, Weiluo Cai, Yong Chen, Wangjun Yan, Chunmeng Wang

Published in: International Journal of Clinical Oncology | Issue 5/2020

Abstract

Background

To describe the clinicopathological features of primary retroperitoneal solitary fibrous tumor (RSFT) and define the prognostic factors.

Methods

The comprehensive data of 35 primary RSFT patients who got curative surgery at a tertiary cancer center from April 2004 to October 2018 were retrospectively analyzed.

Results

Male patients outnumbered female patients (19 vs. 16), with the age ranging from 19 to 73 years (median, 51 years). 7 (20%) patients had tumors located in special parts, including three in kidney, one in renal pelvis, one in bladder, one in prostate, and one in mesentery. Tumor sizes ranged from 2.5 to 25 cm (median, 9 cm). Microscopic negative margin was reached in 33 (94.3%) cases. 13 (37.1%) were classified as atypical/malignant, while 22 (62.9%) were benign. Concomitant organ excision was performed on 11 (31.4%) patients, with kidney (n = 5) being the most frequent organ. Multifocality was only found in 4 (11.4%) cases. The majority of the patients (31, 88.6%) did not get adjuvant treatment. The median follow-up time was 46 months (range 4–153 months). The 5-year DSS rate and DFS rate were 100% and 63.6%, respectively. In univariate analysis, tumor size ≥ 10 cm (P = 0.002) and atypical/malignant pathology (P = 0.024) were associated with decreased DFS. Multivariate analysis revealed that tumor size was the only independent prognostic factor for DFS (HR 6.03, 95% CI 1.18–30.77, P = 0.031).

Conclusion

RSFT is uncommon, slow-growing, and recrudescent tumors. Large tumor size and malignant pathology are associated with decreased DFS. Tumor size ≥ 10 cm independently predicts shortened DFS.

Klemperer P, Coleman BR (1992) Primary neoplasms of the pleura. A report of five cases. Am J Ind Med 22:1–31CrossRef

Stout AP, Murray MR (1942) Hemangiopericytoma. A vascular tumor featuring Zimmerman’s pericytes. Ann Surg 116:26–33CrossRef

Jo VY, Fletcher CD (2014) WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology 46:95–104CrossRef

Robinson DR, Wu YM, Sundaram SK et al (2013) Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45:180–185CrossRef

O'Neill AC, Tirumani SH, Do WS et al (2017) Metastatic patterns of solitary fibrous tumors: a single-institution experience. AJR Am J Roentgenol 208:2–9CrossRef

Demicco EG, Park MS, Araujo DM et al (2012) Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol 25:1298–1306CrossRef

England DM, Hochholzer L, McCarthy MJ et al (1989) Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol 13:640–658CrossRef

Insabato L, Siano M, Somma A et al (2009) Extrapleural solitary fibrous tumor: a clinicopathologic study of 19 cases. Int J Surg Pathol 17:250–254CrossRef

Schirosi L, Lantuejoul S, Cavazza A et al (2008) Pleuropulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR. Am J Surg Pathol 32:1627–1642CrossRef

10.

Cranshaw IM, Gikas PD, Fisher C et al (2009) Clinical outcomes of extra-thoracic solitary fibrous tumours. Eur J Surg Oncol 35:994–998CrossRef

11.

van Houdt WJ, Westerveld CM, Vrijenhoek JE et al (2013) Prognosis of solitary fibrous tumors: a multicenter study. Ann Surg Oncol 20:4090–4095CrossRef

12.

Smith SC, Gooding WE, Elkins M et al (2017) Solitary fibrous tumors of the head and neck: a multi-institutional clinicopathologic study. Am J Surg Pathol 41:1642–1656CrossRef

13.

Jiang N, Xie YY, Chen W et al (2017) solitary fibrous tumor of central nervous system: clinical and prognostic study of 24 cases. World Neurosurg 99:584–592CrossRef

14.

Bisceglia M, Galliani C, Giannatempo G et al (2011) Solitary fibrous tumor of the central nervous system: a 15-year literature survey of 220 cases (August 1996–July 2011). Adv Anat Pathol 18:356–392CrossRef

15.

Tanaka M, Sawai H, Okada Y et al (2006) Malignant solitary fibrous tumor originating from the peritoneum and review of the literature. Med Sci Monit 12:95–98

16.

Rajeev R, Patel M, Jayakrishnan TT et al (2015) Retroperitoneal solitary fibrous tumor: surgery as first line therapy. Clin Sarcoma Res 5:19CrossRef

17.

Dalal KM, Kattan MW, Antonescu CR et al (2006) Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 244:381–391PubMedPubMedCentral

18.

Ronchi A, Cozzolino I, Zito Marino F et al (2018) Extrapleural solitary fibrous tumor: a distinct entity from pleural solitary fibrous tumor. An update on clinical, molecular and diagnostic features. Ann Diagn Pathol 34:142–150CrossRef

19.

Anaya DA, Lahat G, Wang X et al (2010) Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. Ann Oncol 21:397–402CrossRef

20.

Gronchi A, Miceli R, Shurell E et al (2013) Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol 31:1649–1655CrossRef

21.

Katz MH, Choi EA, Pollock RE (2007) Current concepts in multimodality therapy for retroperitoneal sarcoma. Expert Rev Anticancer Ther 7:159–168CrossRef

22.

Mohamed H, Mandal AK (2004) Natural history of multifocal solitary fibrous tumors of the pleura: a 25-year follow-up report. J Natl Med Assoc 96(659–62):664

23.

Tseng WW, Madewell JE, Wei W et al (2014) Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol 21:2136–2143CrossRef

24.

Luo P, Cai W, Yang L et al (2018) Retroperitoneal dedifferentiated liposarcoma: analysis of 61 cases from a large institution. J Cancer 9:3831–3838CrossRef

25.

Ikoma N, Roland CL, Torres KE et al (2018) Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: a retrospective cohort study at a major sarcoma center. J Surg Oncol 117:1188–1194CrossRef

26.

Levard A, Derbel O, Méeus P et al (2013) Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience. BMC Cancer 13:109CrossRef

27.

Park MS, Ravi V, Conley A et al (2013) The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res 3:7CrossRef

28.

Kawamura S, Nakamura T, Ova T et al (2007) Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int 57:213–218CrossRef

29.

Saynak M, Bayir-Angin G, Kocak Z et al (2010) Recurrent solitary fibrous tumor of the pleura: significant response to radiotherapy. Med Oncol 27:45–48CrossRef

Title: Outcome of patients with primary retroperitoneal solitary fibrous sarcoma
Authors: Peng Luo
Zhiqiang Wu
Shiqi Chen
Lingge Yang
Weiluo Cai
Yong Chen
Wangjun Yan
Chunmeng Wang
Publication date: 01-05-2020
Publisher: Springer Singapore
Published in: International Journal of Clinical Oncology / Issue 5/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-020-01617-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2020

Laparoscopic versus abdominal radical hysterectomy for stage IB1 cervical cancer patients with tumor size ≤ 2 cm: a case-matched control study

Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy: a single-center, retrospective study

Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis

Barriers for sperm cryopreservation in advanced germ cell tumor patients: a 20-year experience

Immune-resistant mechanisms in cancer immunotherapy

Treatment strategies for neuroendocrine carcinoma of the upper digestive tract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer